In Brief: Orquest
This article was originally published in The Gray Sheet
Executive Summary
Orquest: Firm plans to commence U.S. clinical trials of its Healos bone grafting material for spinal fusion in early 1998 under an investigational device exemption submission by strategic development partner Spine-Tech, Michael Estes, president and CEO, states at the recent BancAmerica Robertson Stephens conference in New York City. Orquest also has a research agreement with Hoechst Marion Roussel for evaluation of Healos with Hoechst growth factors. The privately held, Mountain View, California firm is also preparing for clinical trials of its Ossigel injectable product for accelerating the healing of fractures...
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.